Please use this identifier to cite or link to this item:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients

AuthorsRivero, Antonio; Torres-Cornejo, Almudena; Ruiz-Valderas, Rosa; Gutiérrez Valencia, Alicia
Issue Date2012
PublisherPublic Library of Science
CitationPLoS ONE 7 (2012)
AbstractBackground: The aim of the study was to analyze the different impact of standard and low-dose Peg-IFN-α2a/RBV therapies on HCV viral decline in HIV/HCV genotype 3 co-infected patients during the first weeks of treatment. Methods: Plasma HCV viral decline was analyzed between baseline and weeks 1, 2 and 4 in two groups of treatment-naïve HCV genotype 3 patients with HIV co-infection. The Standard Dose Group (SDG) included patients who received Peg-IFN at 180 οg/per week with a weight-adjusted dose of ribavirin; Low-Dose Group (LDG) patients received Peg-IFN at 135 οg/per week with 800 mg/day ribavirin. The effect of IL28B genotype on HCV viral decline was evaluated in both groups. HCV viral decline was analyzed using a multivariate linear regression model. Results: One hundred and six patients were included: 48 patients in the SDG and 58 in the LDG. HCV viral decline for patients in the LDG was less than for those in the SDG (week 1:1.72±0.74 log 10 IU/mL versus 1.78±0.67 log 10 IU/mL, p = 0.827; week 2:2.3±0.89 log 10 IU/mL versus 3.01±1.02 log 10 IU/mL, p = 0.013; week 4:3.52±1.2 log 10 IU/mL versus 4.09±1.1 log 10 IU/mL, p = 0.005). The linear regression model identified the Peg-IFN/RBV dose as an independent factor for HCV viral decline at week 4. Conclusions: Our results showed that HCV viral decline was less for patients in the low-dose group compared to those receiving the standard dose. Until a randomized clinical trial is conducted, clinicians should be cautious about using lower doses of Peg-IFN/RBV in HIV/HCV genotype 3 co-infected patients. © 2012 Rivero-Jurez et al.
Identifiersdoi: 10.1371/journal.pone.0048959
issn: 1932-6203
Appears in Collections:(IBIS) Artículos

Files in This Item:
File Description SizeFormat
journal.pone.0048959.pdf232,3 kBAdobe PDFThumbnail
Show full item record
Review this work


checked on May 19, 2022


checked on May 16, 2022

Page view(s)

checked on May 22, 2022


checked on May 22, 2022

Google ScholarTM




WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.